المؤلفون: van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands. a.vandeloosdrecht@amsterdamumc.nl., Cremers EMP; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Alhan C; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Duetz C; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., In 't Hout FEM; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Visser-Wisselaar HA; HOVON Foundation, Rotterdam, The Netherlands., Chitu DA; HOVON Foundation, Rotterdam, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Verbrugge A; HOVON Foundation, Rotterdam, The Netherlands., Cunha SM; HOVON Foundation, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Janssen JJWM; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Klein SK; Department of Hematology, Meander Medisch Centrum, Amersfoort, The Netherlands.; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Vellenga E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Huls GA; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Muus P; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Haematology, St. James University Hospital, Leeds, UK., Langemeijer SMC; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., de Greef GE; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Te Boekhorst PAW; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Raaijmakers MHG; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Marwijk Kooy M; Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands., Legdeur MC; Department of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands., Wegman JJ; Department of Hematology, Deventer Ziekenhuis, Deventer, The Netherlands.; Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands., Deenik W; Department of Internal Medicine, Tergooi Ziekenhuis, Hilversum, The Netherlands.; Department of Internal Medicine, Rijnstate, Arnhem, the Netherlands., de Weerdt O; Department of Internal Medicine, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands., van Maanen-Lamme TM; Department of Internal Medicine, Dijklander Ziekenhuis, Hoorn, The Netherlands., Jobse P; Department of Internal Medicine, Admiraal de Ruyter Ziekenhuis, Goes, The Netherlands., van Kampen RJW; Department of Internal Medicine, Zuyderland Ziekenhuis, Geleen, The Netherlands., Beeker A; Department of Hematology, Spaarne Gasthuis, Hoofddorp, The Netherlands., Wijermans PW; Department of Hematology, Haaglanden Ziekenhuis, Den Haag, The Netherlands., Biemond BJ; Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands., Tanis BC; Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands.; Department of General Practice Erasmus MC, Rotterdam, The Netherlands., van Esser JWJ; Department of Internal Medicine, Amphia Ziekenhuis, Breda, The Netherlands., Schaar CG; Department of Internal Medicine, Gelre Ziekenhuis, Apeldoorn, The Netherlands., Noordzij-Nooteboom HS; Department of Internal Medicine, Van Weel Bethesda Ziekenhuis, Dirksland, The Netherlands., Jacobs EMG; Department of Internal Medicine, Elkerliek Ziekenhuis, Helmond, The Netherlands., de Graaf AO; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Stevens-Kroef MJPL; Department of human genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Westers TM; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Jansen JH; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

المصدر: Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 840-850. Date of Electronic Publication: 2024 Jan 31.

نوع المنشور: Clinical Trial, Phase II; Randomized Controlled Trial; Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Hematinics*/pharmacology , Myelodysplastic Syndromes*/drug therapy , Myelodysplastic Syndromes*/genetics, Humans ; Lenalidomide/pharmacology ; Erythropoiesis ; Granulocyte Colony-Stimulating Factor/pharmacology ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; Treatment Outcome

المؤلفون: Visser C; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Swinkels M; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., van Werkhoven ED; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Croles FN; Department of Internal Medicine, Hospital St. Jansdal, Harderwijk, The Netherlands., Noordzij-Nooteboom HS; Department of Internal Medicine, van Weel-Bethesda Hospital, Dirksland, The Netherlands., Eefting M; Department of Internal Medicine, Beatrix Hospital, Gorinchem, The Netherlands., Last-Koopmans SM; Department of Internal Medicine, Beatrix Hospital, Gorinchem, The Netherlands., Idink C; Department of Internal Medicine, ZorgSaam Hospital, Terneuzen, The Netherlands., Westerweel PE; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Santbergen B; Department of Internal Medicine, IJsselland Hospital, Capelle aan den IJssel, The Netherlands., Jobse PA; Department of Internal Medicine, ADRZ Hospital, Goes, The Netherlands; and., Baboe F; Department of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands., Te Boekhorst PAW; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Leebeek FWG; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Kruip MJHA; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Jansen AJG; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

مؤلفون مشاركون: RECOVAC-IR Consortium

المصدر: Blood advances [Blood Adv] 2022 Mar 22; Vol. 6 (6), pp. 1637-1644.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19*/complications , COVID-19*/epidemiology , COVID-19*/prevention & control , Purpura, Thrombocytopenic, Idiopathic*/complications , Purpura, Thrombocytopenic, Idiopathic*/epidemiology , Thrombocytopenia*/complications , Thrombocytopenia*/etiology, COVID-19 Vaccines/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Vaccination/adverse effects

المؤلفون: van Esch HJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.; Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands.; Laurens Cadenza, Rotterdam, the Netherlands., van Zuylen L; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, the Netherlands., Geijteman ECT; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Huisman BAA; Hospice Kuria, Amsterdam, the Netherlands., Noordzij-Nooteboom HS; Hospice Calando, Dirksland, the Netherlands., Boogaard R; Palliative Care Unit 'de Regenboog,' Rotterdam, the Netherlands., van der Heide A; Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands., van der Rijt CCD; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.

المصدر: JAMA [JAMA] 2021 Oct 05; Vol. 326 (13), pp. 1268-1276.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

مواضيع طبية MeSH: Death*, Butylscopolammonium Bromide/*therapeutic use , Cholinergic Antagonists/*therapeutic use , Respiratory Sounds/*drug effects, Aged ; Aged, 80 and over ; Butylscopolammonium Bromide/administration & dosage ; Butylscopolammonium Bromide/adverse effects ; Cholinergic Antagonists/administration & dosage ; Cholinergic Antagonists/adverse effects ; Confidence Intervals ; Double-Blind Method ; Drug Administration Schedule ; Female ; Hospice Care ; Humans ; Incidence ; Informed Consent ; Injections, Subcutaneous ; Life Expectancy ; Male ; Middle Aged ; Netherlands ; Placebos ; Proportional Hazards Models ; Respiratory Sounds/diagnosis ; Treatment Outcome